Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to expand China R&D

Novo Nordisk is to double the size of its R&D centre in China by 2015

Novo Nordisk is to double the size of its R&D centre in Beijing, China by 2015.

The diabetes specialist said the level of employees at the centre will increase from 100 to 200, with a focus on creating a new Diabetes Research Unit in the country.

 

A picture of a building housing a Diabetes Research Unit in China

Novo Nordisk R&D centre in China

 

"By doubling the current staff at our R&D centre, Novo Nordisk acknowledges the achievements of the Chinese staff since the centre was established in 1997," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Denmark-based Novo Nordisk.

"And once again, we demonstrate our long term commitment to take part in the scientific and technological development of China, while at the same time helping Novo Nordisk to get access to the tremendous resource of talents, ideas and innovation in China."

Since its establishment, the R&D centre has focused on building expertise in protein engineering and purification, as well as creating and improving monoclonal antibodies.

The expansion will see Novo Nordisk research biopharmaceutical approaches to develop new treatments against diabetes.

The company said the R&D team in China "will eventually take part in all aspects of drug discovery, from innovation to developing drug candidates for clinical studies in humans."

14th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics